Overview

• Topline ATTAIN-2 results showed adults with obesity and type 2 diabetes lost a mean 10.5% of body weight at 72 weeks on 36 mg orforglipron versus 2.2% with placebo, with a treatment-regimen analysis showing 9.6% versus 2.5%.
• Glycemic control improved substantially, with HbA1c reductions of about 1.3% to 1.8% across doses and 75% of patients on 36 mg reaching 6.5% or less versus 10.6% on placebo from a baseline of 8.1%.
• Safety was consistent with the GLP-1 class, dominated by gastrointestinal events; at the highest dose nausea occurred in 36.4%, vomiting in 23.1%, diarrhea in 27.4%, and discontinuations due to adverse events were 10.6% versus 4.6% on placebo, with no hepatic safety signals observed.
• The 72-week, randomized study enrolled more than 1,600 participants across 10 countries testing once-daily 6 mg, 12 mg, and 36 mg doses, and also reported improvements in non-HDL cholesterol, systolic blood pressure, triglycerides, and a 50.6% drop in high-sensitivity C-reactive protein at 36 mg in an exploratory analysis.
• Lilly said it now has the full late-stage data package to initiate global regulatory submissions as the pill’s easier use and manufacturing face comparisons with leading injectables and Novo Nordisk’s oral Wegovy, which is already under FDA review.